Background: Epidural-related maternal fever (ERMF) has been reported in~26% of labouring women. The underlying mechanisms remain unclear. We hypothesised that ERMF is promoted by bupivacaine disrupting cytokine production/ release from mononuclear leucocytes [mononuclear fraction (MNF)]. We examined whether bupivacaine (i) reduces caspase-1 activity and release of the anti-pyrogenic cytokine interleukin (IL)-1 receptor antagonist (IL-1ra), and (ii) is proinflammatory through mitochondrial injury/IL-1b. Methods: In labouring women, blood samples were obtained before/after epidural analgesia was implemented. Maternal temperature was recorded hourly for the first 4 h of epidural analgesia. Time-matched samples/temperatures were obtained from labouring women without epidural analgesia, pregnant non-labouring, and non-pregnant women. The primary clinical outcome was change in maternal temperature over 4 h after the onset of siting epidural catheter/enrolment. The secondary clinical outcome was development of ERMF (temperature ! 38 C). The effect of
Fever related to epidural labour analgesia is common and can lead to additional interventions and treatments with associated complications; yet, its mechanisms are unclear. In a combined clinical study and ex vivo laboratory investigation of blood from labouring women and controls, fever occurred only in those receiving epidural analgesia. Bupivacaine impaired release of the anti-pyrogenic cytokine interleukin-1 receptor antagonist from circulating leucocytes by reducing the activation of caspase-1. Immunomodulation of inflammatory cytokines thus appears to underlie epidural-related maternal fever.
Epidural-related maternal fever (ERMF) has been reported iñ 26% of women who receive epidural analgesia during labour. 1 Intra-partum fever is associated with more frequent obstetric interventions,~30% higher rate of (unnecessary) antibiotic administration, 2 lower rates of spontaneous vaginal delivery, and excess neonatal morbidity. 3 However, the molecular mechanism(s) underlying ERMF remain unclear. 4 The maternal compartment may be the primary source of inflammation, 5, 6 as an infectious placental aetiology is absent in the majority of women with ERMF. 7 Fever requires the systemic release of pyrogenic cytokines, chiefly interleukin (IL)-6 and IL-1b. 8 Fever is inhibited by the anti-pyrogenic cytokine IL-1 receptor antagonist (IL-1ra), 8 which directly inhibits the pro-inflammatory effects of IL-1b through binding to the IL-1 receptor. Modulation of IL-1b or IL1ra by local anaesthetic agents used routinely for obstetric analgesia is a plausible mechanism underlying ERMF. 1 Local anaesthetics exert anti-and pro-inflammatory effects in a dose-dependent tissue-specific manner. 9 Bupivacaine might promote inflammation through mitochondrial damage, triggered by the uncoupling of mitochondrial oxidative phosphorylation and inhibiting mitochondrial respiratory chain complexes. 10e12 The resultant increase in reactive oxygen species (ROS) production is similar to that driven by acute systemic inflammation, which repurposes mitochondrial function from ATP synthesis to production of ROS. 13 Metabolic reprogramming and ROS generation activate the NACHT, LRR, and PYD domains-containing protein 3 (NLRP3) inflammasome, 14, 15 one of several that promote maturation and secretion of IL-1b and IL-18, and the subsequent downstream release of fever-inducing cytokines. Caspase-1 is essential for the formation of the NLRP3 complex and IL-1b production in leucocytes, 15 but also for triggering cell death and regulating the release of IL-1ra through unconventional protein secretion. 16 ERMF is associated with increases in maternal and umbilical cord serum inflammatory cytokines. 6 Therefore, we hypothesised that ERMF is promoted by bupivacaine disrupting cytokine production/release from mononuclear leucocytes [mononuclear fraction (MNF)] during established labour by altering caspase-1 and NLRP3 activity. To test this hypothesis, we first examined whether clinically relevant concentrations of bupivacaine altered leucocyte metabolism (using a THP-1 human monocyte cell line). We further examined whether regulation of cytokine release in mononuclear leucocytes by bupivacaine was specific to women in established labour by comparing leucocyte biology in four populations: labouring women with and without epidural analgesia, non-labouring pregnant women before elective Caesarean delivery, and non-pregnant women undergoing other elective surgery.
Methods

Subjects
This study was conducted at the University College London Hospitals NHS Trust (ISRCTN11281491) from October 2014 to May 2016. Ethical approval was obtained from the South Central Oxford National Research Ethics Service Committee (reference: 14/SC/1160). All women recruited into the study provided written consent to participate in this study. Four populations of women were recruited into this single-centre, observational, mechanistic cohort study: (i) women in established labour who requested epidural analgesia, (ii) women in established labour who did not receive epidural analgesia, (iii) non-labouring pregnant women before elective Caesarean delivery, and (iv) non-pregnant women of childbearing age undergoing (non-obstetric) elective surgery ( Supplementary Fig. S1 ). The inclusion criteria for labouring women were !18 yr old, !37 weeks gestation, singleton pregnancy, and confirmed to be in established labour (>3 cm dilatation with regular uterine contractions). The exclusion criteria were pre-eclampsia, hypertensive disorder of pregnancy, pre-existing immune dysfunction, known infection or pyrexia, current antibiotic prescription, and NSAID use. For the other two (non-labour) groups, we recruited age-matched women who satisfied the same exclusion criteria.
Women in labour
Labouring women on the labour ward were recruited into the epidural analgesia arm of the study, and labouring women in the birthing centre (midwife led without availability of epidural analgesia) were recruited into the non-epidural analgesia arm of the study. All women had access to inhaled oxygen/nitrous oxide and i.m. diamorphine. Women requesting epidural analgesia whilst on the birthing centre are transferred to the labour ward before epidural catheter insertion. Because pregnancy is a transient physiological period of increased cortisol release with maintained diurnal variation of plasma concentrations, 17 recruitment was standardised by the time of data collection (morning) to minimise confounding influences on immune function. Women were recruited on weekday mornings when research fellow and laboratory researchers were available to recruit subjects, collect data, and perform experiments. Subjects recruited to the pregnant nonlabouring and -pregnant arms of the study were approached on the morning of their elective Caesarean delivery and elective non-obstetric surgery, respectively.
Epidural catheter insertion and analgesia regimen
Before epidural catheter insertion, labouring women in our institution upon request can receive Entonox™, BOC Healthcare, Manchester, UK (oxygen and nitrous oxide) and a single dose of i.m. diamorphine 7.5 mg. After verbal and written consent to participate in the study, a 16G i.v. catheter was placed. An epidural catheter was sited in the mid-lumbar epidural space using a loss of resistance to saline technique. After negative aspiration, an initial dose of bupivacaine 0.1%, 15 ml/fentanyl 2 mg ml À1 (low-dose mixture) in three divided doses of 5 ml each, 5 min apart (with regular vital sign assessment) was given, and the catheter was subsequently connected to a patient-controlled epidural analgesia pump (Smiths Medical, Ashford, UK) administering an 8 ml bolus of the low-dose solution with a 20 min lockout.
Clinical outcomes
The primary clinical outcome was change in maternal oral temperature more than 4 h after the onset of siting of the epidural catheter, or 4 h after enrolment for labouring women who did not receive epidural analgesia (Fig 1a) . A previous study reported that maternal temperature increases after epidural analgesia over a similar period. 18 During labour, oral temperature correlates most closely with intrauterine temperature and is recommended for routine detection of maternal pyrexia in labour. 19 We therefore measured oral temperature (SureTemp ® Plus 690 thermometer; Welch Allyn, Aylesbury, UK; calibration accuracy plus/minus 0.1 C) hourly in each labour group (epidural or no epidural analgesia) immediately after written consent and before epidural catheter placement in the epidural analgesia group. Subsequent temperatures were measured at hourly intervals for 4 h after the first blood sample and the temperature reading were acquired.
For secondary clinical outcomes, we recorded episodes of ERMF (maternal oral temperature !38 C) during labour up to delivery, requirement for sepsis or fever evaluation, and indications for antibiotic use. Patients, attending clinicians, and critical care staff were blinded to the laboratory data, and the laboratory staff was blinded to subject details, including temperature.
Isolation of primary leucocytes
Patient leucocytes were isolated using the density gradient technique (Ficoll ® Plus; BD Biosciences, Oxford, UK) within 20 min of venous whole-blood sampling (10 ml) as described. 20 Residual erythrocytes were eliminated by hypotonic buffer lysis.
Flow cytometry
For flow-cytometry gating strategy and antibodies used, see Supplementary methods. All flow-cytometry measurements were conducted on !10 000 cells (FACSCalibur™, BD BIosciences, Wokingham, UK). Cell debris and dead cells were 
Laboratory experiments
Five mechanistic questions were addressed in the laboratory, which are summarised in Table 1 . We used 10mM bupivacaine based on plasma concentrations measured after low-dose epidural infusion in labour, 21 and transversus abdominal plane blocks after Caesarean section. 22 This concentration is below levels associated with systemic effects 23 and toxicity (!17mM).
24
Experiment 1: does bupivacaine cause cell death, and hence, inflammation through mitochondrial dysfunction?
We quantified changes in mitochondrial respiration and glycolysis using the Seahorse XFe96 analyser by measuring oxygen consumption and extracellular acidification rates, as described (see Supplementary data for full details). 20 We assessed whether bupivacaine or circulating inflammatory mediators in pooled plasma obtained from women in established labour triggered mitochondrial dysfunction in the THP-1 human monocytic leukemic cell line (InvivoGen, San Diego, CA, USA). This cell line is commonly used for the study of inflammasome activation, as THP-1 cells express high concentrations of NLRP3, inflammasome adaptor protein apoptosis-associated speck-like protein containing caspase recruitment domain (ASC), and pro-caspase-1. 25 We also examined whether the absence of NLRP3 inflammasome in THP-1-/NLRP3-deficient cells (THP1-defNLRP3; InvivoGen) altered the effects evoked by bupivacaine. 26 Metabolic measurements were made in the presence/ absence of bupivacaine. At least six measures were made per genotype/serum sample. As a total of 92 wells were available for cell plating, some experimental (genotype/treatment) combinations were assayed in seven, rather than six, wells. All measurements were corrected to total protein content for each well (BCA Protein Assay; Pierce Biotechnology). Glycolysis was quantified concomitantly by measuring the extracellular acidification rate. Spare respiratory capacity, which serves as a measure of the extra capacity available within cells to respond rapidly to acute increases in metabolic demand, was calculated as the difference between ionophore-induced (maximal) and basal rate of oxygen consumption. Further details are provided in Supplementary material (methods).
Experiment 2: does bupivacaine cause cell death, and hence, inflammation through increased apoptosis?
We used samples obtained from women who did or did not receive epidural analgesia at the beginning of the time period over which maternal temperature was measured (Fig 1a) . Ex vivo monocytes and lymphocytes from the same women in established labour were incubated with bupivacaine for the 4 h period (Fig 1b) to mimic the amount of time these cells were exposed to bupivacaine in vivo. Annexin V staining was performed as described (see Supplementary methods for flowcytometry density plots). 20 At least 5 Â 10 5 mononuclear cells were washed in phosphate-buffered saline (PBS), and then resuspended in Annexin buffer (100 ml) containing Annexin V FITC or PI, or buffer alone. Early apoptosis was quantified as a percentage of the whole population of cells expressing Annexin V FITC (PI negative).
Experiment 3: does pregnancy or established labour alter caspase-1 activation in the presence/absence of bupivacaine?
Mononuclear cells were obtained from three groups of women: (i) those in established labour (epidural or non-epidural analgesia), (ii) non-pregnant women before elective surgery, and (iii) pregnant women not in labour. Using the 4 h time period shown in Figure 1b , we quantified caspase-1 activity by flowcytometry pre-and post-epidural, or after 4 h of ex vivo incubation, using the fluorochrome-labelled inhibitors of caspases technique (ImmunoChemistry Technologies, AbD Serotec, Oxford, UK). This in vitro assay exploits the properties of a cellpermeant fluorescent inhibitor probe FAM-YVAD-FMK to label established caspase-1 in living cells. 20 Green fluorescence serves as a direct measure of the caspase-1 activity present in the cell at the time the reagent was added. All cells were fixed and analysed within 1 h. Nigericin and gramicidin (both 10mM), which activate caspase-1 and inflammasome formation, were used as positive controls in each experiment.
Experiment 4: does bupivacaine alter IL-1ra release in leucocytes obtained from women in established labour?
Monocytes and lymphocytes obtained from women in established labour were incubated with 10mM bupivacaine (Fig 1b) to establish its impact on the release of intracellular IL-1ra. After fixation for CD14/CD3/CD19 surface staining, cells were permeabilised (Cytofix/Cytoperm™; BD Biosciences, UK) to enable intracellular staining for IL-1ra expression (AF-280-NA; R&D Systems, Abingdon, UK).
Experiment 5: does bupivacaine alter plasma IL-1ra/IL-1b ratio in women in established labour?
We quantified plasma IL-1ra and IL-1b in paired plasma samples obtained before initiation of epidural analgesia and 4 h later; time-matched samples were also obtained from women who received non-epidural analgesia. IL-1ra/IL-1b ratios were calculated for each sample, which reflect the balance between pro-inflammatory IL-1b and anti-inflammatory IL-1ra components of the NLRP3 inflammasome. 27 We used a solid-phase enzyme-linked human IL-1ra/IL-1F3 immunoassay that measures IL-1ra in duplicate plasma samples (100 ml each), referenced to an Escherichia coli-derived recombinant human IL-1ra (R&D Systems). Intra-assay precision has a coefficient of variation (CV) of 3.7e7.3%; inter-assay CV is 6.7e11% (standard curve is shown in Supplementary Fig. S2 ). We measured the plasma IL-1b by colorimetric enzyme assay. HEK-Blue™ IL-1b cells (InvivoGen, Toulouse, France) were used to detect bioactive IL-1b, which binds to the IL-1R surface receptor. Subsequent activation of the NF-kB/AP-1-inducible secretion of embryonic alkaline phosphatase (SEAP) reporter gene leads to the production of SEAP. SEAP was quantified by a colorimetric enzyme assay (QUANTI-Blue™; InvivoGen) referenced to a known concentration of recombinant human IL-1b. 
Statistical analysis
For continuous data, the normality of distribution was assessed (KolmogoroveSmirnov test). As indicated, data were analysed with paired t-test, and one-way or two-way analysis of variance (with TukeyeKramer post hoc testing). Mean (standard deviation) or median (25-75th centile) values are presented, unless stated otherwise. Correlation between bupivacaine concentration and change in caspase-1 activity was also evaluated by linear regression. All reported P-values are two sided. Significance was accepted for P 0.05. Statistical analyses were performed using NCSS 11 (NCSS, Kaysville, Utah, USA).
Sample size calculation
Sample size was calculated for both clinical and mechanistic experiments in accord with design principles for these types of studies. 28 We hypothesised that early biological changes and temperature increase are plausibly linked with ERMF, and can be detected by the laboratory experiments. ERMF occurs in up to 26% labouring women after epidural analgesia. 1 With a predicted incidence of fever of at most 3% in the non-epidural analgesia group, a sample size of !33 women would be required to detect ERMF (a¼0.05; 1-b¼80%), which was increased to 38 women for a potential dropout rate~25%. This sample-size calculation is similar to a study, in which temperature increase was measured for 4 h in 40 labouring women who received epidural analgesia compared with 13 women who received parenteral opioids (a¼0.05; 1-b¼80%). From our previous studies, detecting biologically significant changes in caspase-1 activity would require !7 paired samples per experimental group. 20 
Results
Subject characteristics
Women in the epidural and non-epidural groups shared similar characteristics (Table 2 ). There was no significant difference between stages of labour (cervical dilatation) at the time of recruitment of labouring women with/without epidural analgesia. Several subjects did not have blood drawn for serial paired analyses ( Supplementary Fig. S1 ), including age-/weight-matched pregnant women not in established labour and women presenting for elective gynaecological surgery (Supplementary Table S1 ).
Primary clinical outcome: serial maternal temperature measurements during labour
All labouring subjects were afebrile and without clinical evidence of infection at the beginning of the study. None had experienced premature rupture of membranes. A single dose of i.m. diamorphine was administered to eight of 38 subjects before epidural analgesia. In the epidural group, the subjects received a mean bupivacaine dose of 52 (20) mg. Four hours after baseline measurement of oral temperature, the mean temperature was greater than baseline in the epidural, but not in the non-epidural, group (Fig 1c) . No subjects developed ERMF within this initial 4 h study period. Women in the non-epidural analgesia group all received nitrous oxide and oxygen for variable durations; four of 15 patients also received a single dose of i.m. diamorphine 7.5 mg during labour.
Secondary clinical outcomes
ERMF was recorded in five of 38 (13.2%) women before delivery. All five women were assessed for suspected sepsis during labour. In contrast, in labouring women who did not receive epidural analgesia, we did not record a single episode of fever (maternal temperature !38 C before delivery) or any sepsis workup during labour. In the non-epidural analgesia group, prophylactic antibiotics were administered to one of 15 (6.6%) before delivery (for confirmed Group B Streptococcus), compared with four of 38 (10.5%) subjects who had epidural analgesia. Four of fifteen (26.7%) subjects converted to epidural analgesia after the initial (4 h) study period during which they received opiate analgesia.
Laboratory measures
Spare respiratory capacity, a measure of metabolic reserve, was similar in the presence/absence of 10mM bupivacaine (Fig 2a; Supplementary Figs S3 and S4) . Similarly, lipopolysaccharide increased glycolysis (P<0.001), but no difference was observed between control vs bupivacaine-treated samples (Fig 2b; Supplementary Figs S3 and S4 ). (Fig 2c and d) . We observed similar apoptosis in lymphocytes obtained 4 h after epidural analgesia (Supplementary Fig. S5 ).
We next assessed whether bupivacaine (10mM) altered caspase-1 activity in mononuclear leucocytes obtained before epidural analgesia was instituted in labouring women (n¼10 paired samples; Fig. 3aee ). Mononuclear leucocyte cells incubated for 4 h with bupivacaine had reduced caspase-1 activity in CD3 þ lymphocytes (Fig 3a and b) by 14% (95% CI: 5e16%).
After epidural analgesia was instituted, reduced caspase-1 activity correlated with the dose of bupivacaine that five subjects required for analgesia during the 4 h period (R 2 ¼0.88;
P¼0.02; Fig 3c) . A decline in caspase-1 activity was also observed in CD14 þ monocytes ( Supplementary Fig. S6 ).
To test whether the effect of bupivacaine on caspase-1 activity in leucocytes was dependent on the acute inflammation associated with established labour, we obtained mononuclear leucocytes from six age-and gestation-matched women not in established labour in whom blood samples were obtained before elective Caesarean section. As in established labour, bupivacaine reduced caspase-1 activity in CD3 þ lymphocytes incubated for 4 h with serum obtained from subjects in established labour before epidural catheter insertion (P<0.001; left panel, Fig 3d) . In contrast, MNF caspase-1 activity was unchanged when CD3 þ lymphocytes were incubated with non-labouring pregnant subject serum from elective Caesarean delivery subjects (P¼0.14; right panel, Fig 3d) . Similarly, caspase-1 activity was unchanged after bupivacaine treatment for 4 h in samples obtained from (non-pregnant) subjects before elective laparoscopic gynaecological surgery (n¼9; P¼0.68; Fig 3e; Supplementary Fig. S7 ).
Experiment 4: does bupivacaine alter IL-1ra release in leucocytes obtained from women in established labour?
As we found that bupivacaine consistently reduced caspase-1 activity in labouring subjects, we reasoned that reduction in caspase-1 activity after bupivacaine may limit the release of the anti-pyrogenic cytokine IL-1ra, and therefore, increase the likelihood of ERMF. Intracellular IL-1ra protein concentrations were increased when leucocytes were incubated with bupivacaine for 4 h compared with control (P<0.001; n¼10 labouring subjects; Fig. 4aec ).
Samples from women in established labour showed that plasma IL-1ra/IL-1b ratio only declined in labouring women who received epidural analgesia (P¼0.017; Fig 4d) . Plasma IL-1b did not differ between analgesic regimes ( Supplementary  Fig. S8 ).
Discussion
The main clinical findings of our study are consistent with a similar prospective study where women receiving epidural analgesia had a significant increase in temperature after 4 h of analgesia, a trend that was absent in women who received parenteral opioids only for analgesia. 18 Moreover, the ERMF rate was similar in our study to the~20% incidence identified from 22 studies by a systematic review. 1 Our mechanistic data revealed three main findings. First, bupivacaine reduces caspase-1 activity in circulating mononuclear leucocytes obtained from women in labour. Second, the reduction in caspase-1 activity in mononuclear cells incubated with clinically relevant concentrations of bupivacaine was mimicked by adding serum obtained from women in established labour. Third, the reduction in caspase-1 activity was paralleled by reduced release and higher intracellular levels of IL-1ra, indicating that bupivacaine appears to impair the release of this anti-pyrogenic cytokine. Taken together, these data suggest that bupivacaine, at clinically relevant concentrations, can disrupt pivotal elements of inflammasome-related biology in leucocytes during established labour, thereby increasing the risk of ERMF. Our data offer an explanation that reconciles the apparently paradoxical observation in many ERMF studies that have reported a similar increase in pro-inflammatory cytokines in both women receiving epidural and non-epidural analgesia. 5 In humans, a ratio of IL-1ra/IL-1b >100 appears to correlate with functional inhibition of the biological effects of IL-1b. 29, 30 It therefore seems likely that the increase in pro-pyrogenic cytokines only results in fever when the release of IL-1ra, an endogenous anti-pyrogenic antagonist, is reduced. Our finding that ERMF may be promoted by impaired IL-1ra release (as summarised in Supplementary Fig. S9 ) is supported by laboratory and clinical work implicating this cytokine in fever, including studies performed in pregnancy. First, recombinant IL-1ra decreases fetal systemic inflammation generated by the release of IL-1b through chorioamnionitis in sheep. 31 Similarly, in rats, placental inflammation stimulated by microbial challenge is alleviated by the co-administration of IL-1ra. 32 Second, familial Mediterranean fever that is refractory to colchicine prophylaxis has been successfully treated with anakinra, an IL-1 blocking agent. 33 Third, the variability in the incidence of ERMF may be accounted for, in part, by IL-1ra gene polymorphisms. Two common variants located upstream of IL1RN, the gene encoding IL-1ra, are the strongest known genetic determinants of increased soluble IL1ra concentration. The frequency of IL-1ra-raising alleles is 30% for the rs6743376 variant and~50% for rs1542176. 34 We did not find any metabolic/mitochondrial evidence for bupivacaine being injurious in either a cell line model or mononuclear cells obtained from women in labour. Taken together, these data suggest that bupivacaine is not directly injurious to mononuclear cells in vitro or ex vivo at clinically relevant concentrations. Many preceding studies exploring the toxic effects of bupivacaine have used far higher concentrations (frequently in the millimolar range) that exceed clinically safe levels. 35, 36 We used a monocyte cell line for three principle reasons. First, attaining sufficient numbers of monocytes from patients for respirometry is challenging with a limited volume of patient blood. Using this established THP-1 model in a standardised manner enables a reproducible picture of acute changes in immune metabolism triggered by acute inflammation. 25 Second, THP-1 cells have high IL-1ra activity. Third, in monocytes, caspase-1 activation is uncoupled from pathogen-associated molecular pattern recognition (in contrast to macrophages that require TLR ligands and a subsequent ATP stimulus). 37 The strengths of this study include the early measurement of temperature during established labour, which were coupled with time-matched ex vivo studies. This approach enabled us to study leucocyte biology over the same time period, during which cellular changes may develop that predispose/ contribute to developing fever. The clinical study was adequately powered to detect ERMF, as suggested by our literature review. 1 Similarly, the sample sizes in laboratory investigations were adequate based on our previous work detailing biologically relevant changes in caspase-1 activity, 20 and in accord with recommendations on devising translational studies in humans. 28 Real-time, rapid laboratory assays of leucocytes masked to clinical details were obtained from both labouring women before epidural catheters were sited and those who initially chose not to have epidural analgesia. Because pregnancy is a transient but physiological period of increased cortisol release with maintained diurnal variation of plasma cortisol concentrations, 17 laboratory assays were standardised by the time of data collection (morning) to minimise confounding influences on immune function. The main limitations for the secondary clinical and mechanistic outcome studies were the 26.7% conversion rate from non-epidural to epidural analgesia (after the 4 h temperature study period) and the unpredictable availability of samples for the timely processing of real-time laboratory assays in a significant number of subjects. Furthermore, patient refusal to participate (chiefly in the non-epidural analgesia group) limited the number of paired samples. We acknowledge that labouring women received epidural analgesia in a physically separate location (labour ward) with obstetrician-guided management, in contrast to women in the birthing centre where care was led by midwives.
Mechanistically, assessing circulating leucocytes was an accessible first step, but the impact of bupivacaine on caspase-1-mediated cytokine release from leucocytes that accumulate in gestational tissues and the placenta may be more substantial during established labour. 38 Finally, we appreciate that modes of analgesia may be difficult to compare owing to the fact that women choosing epidural analgesia may experience more painful, longer, and more complicated labour compared with women selecting other less invasive analgesic modalities. Furthermore, in murine models, acute infection produces pain by directly activating sensory neurones that modulate inflammation. 39 In summary, the mechanism underlying ERMF may involve bupivacaine impairing the release of the anti-pyrogenic cytokine IL-1ra from circulating leucocytes by reducing the activation of caspase-1. Whilst our preliminary cytokine-based data require clinical validation in larger cohorts of women, a more detailed mechanistic understanding of the inflammatory biology associated with epidural analgesia during labour may help refine the obstetric management of fever through development of a novel, precision medicine approach.
